Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04123574
Recruitment Status : Withdrawn (No longer relevant to field)
First Posted : October 11, 2019
Last Update Posted : February 24, 2022
IQVIA Biotech
Information provided by (Responsible Party):
BioXcel Therapeutics Inc

Brief Summary:
A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

Condition or disease Intervention/treatment Phase
Cancer of Pancreas Cancer of the Pancreas Neoplasms, Pancreatic Pancreas Cancer Pancreatic Cancer Drug: Talabostat Mesylate Early Phase 1

Detailed Description:

This is a Phase 0 or "window of opportunity" study where paired specimen analysis, taken before and after drug exposure, will permit the evaluation of target modulation and assessment of immune effector cell infiltration into the tumor and the generation of relevant immune cytokines.

In this study, BXCL701 will be administered at a dose of 0.3 mg, twice daily for a total daily dose of 0.6mg (the previously defined maximum tolerated dose [MTD] of the drug), to all patients for a short period of 14 days. This study is designed to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer
Estimated Study Start Date : October 15, 2019
Estimated Primary Completion Date : December 6, 2021
Estimated Study Completion Date : December 6, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single Arm
BXCL701 will be administered for one week at a dose of 0.2 mg, twice daily (BID). If BXCL701 is well-tolerated after the first week of treatment, the dose will be increased to 0.3mg BID for a total daily dose of 0.6mg to all patients for the second week of treatment.
Drug: Talabostat Mesylate

BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.

Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.

Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.

On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day.

Other Name: BXCL701

Primary Outcome Measures :
  1. To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action. [ Time Frame: Up to 37 days post treatment ]
    To measure how BXCL701 effects the tumor by measuring the rate of tumor cell death or the reduction of tumor cell growth. This will be measured by scans and blood work.

Secondary Outcome Measures :
  1. Evaluate the tolerability of exposure to BXCL701: National Cancer Institute Common Terminology Criteria [ Time Frame: Up to 37 days post treatment ]
    assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events

  2. Evaluate the effect of exposure to BCXL701 on cancer cell death [ Time Frame: Up to 37days post treatment ]
    Measure the rate of cancer cell death measured by histological staining methods of post-treatment biopsied tissue.

  3. Genomic analysis before and after treatment. [ Time Frame: Up to 37 days post treatment ]
    Genomic analysis is the identification, measurement or comparison of genomic features such as DNA sequence, structural variation, gene expression, or regulatory and functional element annotation at a genomic scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has untreated (eg, no prior investigational therapies, chemotherapy, or radiation therapy), locally advanced or metastatic adenocarcinoma of the head, neck, uncinate process, or tail of the pancreas with a local or metastatic lesion that is amenable to biopsy before and after treatment. (Whenever possible, the before and after treatment biopsies should be from the same lesion.)
  2. Is able and willing to undergo tumor biopsy before and after treatment. (A pretreatment biopsy may not be needed if tissue is available from a biopsy conducted within 28 days prior to screening that is adequate for the study assessments.)
  3. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  4. Is 18 to 75 years of age, inclusive
  5. Has adequate organ function within 28 days of treatment initiation
  6. For participants with exposure to prior agents associated with decreased left ventricular ejection fraction (LVEF) (e.g. anthracyclines), or if clinically warranted, a documented LVEF > 45% using a standard echocardiogram (ECHO) or multigated acquisition (MUGA) scan test at Screening or within 60 days prior to Cycle 1 Day 1. ECHO or MUGA testing for other participants without relevant medical history or clinical symptoms can be performed if feasible.
  7. Has oxygen saturation ≥ 92% on room air.
  8. Is able to take an oral medication.
  9. Has signed an Informed Consent Form (ICF) prior to the initiation of any study-specific procedures or treatment.
  10. Is willing and able to adhere to the study visit schedule and other protocol requirements.
  11. Women of childbearing potential (WOCBP) must have a negative pregnancy test at baseline. A woman must be menopausal for at least 12 months before she is considered not to be of reproductive potential.
  12. Male and female patients of reproductive potential must agree to use an effective contraceptive method during participation in this study and for 6 months following the study.

Exclusion Criteria:

  1. A female who is pregnant or breast-feeding.
  2. Has other concurrent malignancies except for basal and squamous cell cancers of the skin and in-situ cervical cancer.
  3. Has uncontrolled epilepsy, central nervous system diseases, or a history of mental disorder that is severe enough to hinder the ability of the patient to provide informed consent or that may influence the patient's compliance with the protocol in the judgments of the investigator.
  4. Has an upper gastrointestinal obstruction, abnormal physiological function, or malabsorption syndrome that may affect the absorption of study medication.
  5. Has required chronic corticosteroids, defined as > 10 mg/day of prednisone or equivalent, or immunosuppressive therapy within the past 3 months. Patient requires treatment with DPP4 inhibitors (e.g. gliptins).
  6. Has a premalignant hematologic disorder, eg, myelodysplastic syndrome.
  7. Has a severe organ dysfunction or disease that might prevent completion of the treatment regimen, eg, cardiopulmonary diseases (New York Heart Association [NYHA] ≥ Class III, arrhythmia Lown III/IV, global respiratory insufficiency); ascites; acute pancreatitis; bleeding diathesis, coagulopathy, or need for full dose anticoagulation.
  8. Has a chronic infectious disease, especially immune deficiency syndromes, eg, human immunodeficiency virus (HIV) infection, active tuberculosis within 12 months prior to potential study participation or suspected/active SARS-CoV-2 (Covid-19) infection.
  9. Has a history of severe neurologic disorders, eg, cerebrovascular ischemia within the past year.
  10. Has a history of prior deep venous thrombosis or pulmonary embolism within the past year.
  11. Has serious medical, psychological, familial, sociological, or geographical conditions or circumstances potentially hampering compliance with the study protocol and follow-up.
  12. QT interval corrected for heart rate using Bazett's formula (QTcB) > 440 msec at Screening.
  13. Patients with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04123574

Layout table for location information
United States, Massachusetts
BioXcel Clinical Research Site
Boston, Massachusetts, United States, 02215
United States, New York
BioXcel Clinical Research Site
New York, New York, United States, 10021
Sponsors and Collaborators
BioXcel Therapeutics Inc
IQVIA Biotech
Layout table for additonal information
Responsible Party: BioXcel Therapeutics Inc Identifier: NCT04123574    
Other Study ID Numbers: BXCL701-001
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioXcel Therapeutics Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases